Machine learning model developed to predict brain amyloid beta accumulation
Oita University and Eisai introduce a model for primary care physicians to facilitate early screening for Alzheimer’s disease
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Alzheimer’s disease
Global Alzheimer’s disease market to reach $19.3 bn in 8MM by 2033
GlobalData’s latest report reveals that, by 2033, DMTs are expected to dominate the global AD market, contributing 73.5 per cent…
Elucidation of part of the mechanism by which Lecanemab slows the progression of Alzheimer’s
Measuring the Lec-PF concentration in CSF before and after lecanemab treatment may be useful in assessing the efficacy of…
Biomarkers becoming important for approval of ALS therapies: GlobalData
Understanding the integrated stress response is an important next step towards grasping the importance of target engagement…
Exploring new avenues to treat Alzheimer’s
Dr Devendra Kumar, Assistant Professor, NMIMS SPTM Shirpur shares details of his study In funded by the ICMR. He informs that his…
When proteins get stuck at solid: Unlocking the secrets to brain diseases
Nanoscale view of proteins opens window to treat neurodegenerative illness
Eisai submits MAA for lecanemab in Great Britain to treat early Alzheimer’s disease
Lecanemab has been designated by the MHRA for the Innovative Licensing and Access Pathway
USFDA accepts Eisai’s sBLA and grants priority review for approval of LEQEMBITM…
USFDA accepts Eisai's sBLA and grants priority review for approval of LEQEMBITM Alzheimer's treatment
Biogen gets US FDA accelerated approval for Aduhelm to treat Alzheimer’s
It is the first new treatment approved for Alzheimer's since 2003 and is the first therapy that targets the fundamental…
Re-purposed drugs could reverse blood vessel damage in diabetes
In a breakthrough, scientists have discovered a key mechanism that triggers changes in the blood vessels, which can eventually…